OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China
Changying Shi, Yulong Li, Cheng‐Ta Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Changying Shi, Yulong Li, Cheng‐Ta Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Showing 1-25 of 28 citing articles:
IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma
Haijiao Yan, Qian Deng, Yu Meng, et al.
Cancer Biotherapy and Radiopharmaceuticals (2025)
Closed Access | Times Cited: 1
Haijiao Yan, Qian Deng, Yu Meng, et al.
Cancer Biotherapy and Radiopharmaceuticals (2025)
Closed Access | Times Cited: 1
Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
Ziting Peng, Jianhui Dong, Shuyao Tang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Ziting Peng, Jianhui Dong, Shuyao Tang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
Chengpei Zhu, Hu Li, Xiaobo Yang, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 9, pp. 2949-2960
Open Access | Times Cited: 17
Chengpei Zhu, Hu Li, Xiaobo Yang, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 9, pp. 2949-2960
Open Access | Times Cited: 17
The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
Rongce Zhao, Jing Zhou, Zhaoxia Miao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Rongce Zhao, Jing Zhou, Zhaoxia Miao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma
YeXing Huang, ZeFeng Du, Anna Kan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
YeXing Huang, ZeFeng Du, Anna Kan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer
Ting Zhang, Chengpei Zhu, Nan Zhang, et al.
International Immunopharmacology (2024) Vol. 129, pp. 111642-111642
Closed Access | Times Cited: 4
Ting Zhang, Chengpei Zhu, Nan Zhang, et al.
International Immunopharmacology (2024) Vol. 129, pp. 111642-111642
Closed Access | Times Cited: 4
Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 4
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 4
The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study
Yuanze Cai, Wu Wen, Ying Xia, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 87-87
Open Access
Yuanze Cai, Wu Wen, Ying Xia, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 87-87
Open Access
Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study
Yichen Zheng, Jiamin Guo, Tianhui Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Yichen Zheng, Jiamin Guo, Tianhui Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice
Long-Wang Lin, Kun Ke, Rong Chen, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 3
Long-Wang Lin, Kun Ke, Rong Chen, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 3
Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer
Shiwei Yue, Yunpu Zhang, Wei Zhang
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 8, pp. 1089-1111
Open Access | Times Cited: 3
Shiwei Yue, Yunpu Zhang, Wei Zhang
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 8, pp. 1089-1111
Open Access | Times Cited: 3
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
Wei Zhang, Luo Chu, Zun-Yi Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
Wei Zhang, Luo Chu, Zun-Yi Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma
Zhanqi Wei, Yajing Wang, Boyang Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Zhanqi Wei, Yajing Wang, Boyang Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date
Michael H. Storandt, Zhaohui Jin, Amit Mahipal
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 383-394
Open Access | Times Cited: 2
Michael H. Storandt, Zhaohui Jin, Amit Mahipal
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 383-394
Open Access | Times Cited: 2
Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
Yunchao Wang, Nan Zhang, Jingnan Xue, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Yunchao Wang, Nan Zhang, Jingnan Xue, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
Annalisa Schirizzi, G Leonardis, V. Lorusso, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2376-2376
Open Access | Times Cited: 6
Annalisa Schirizzi, G Leonardis, V. Lorusso, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2376-2376
Open Access | Times Cited: 6
Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study
Shanshan Wang, Jiashuo Chao, Hao Wang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 1
Shanshan Wang, Jiashuo Chao, Hao Wang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 1
Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review
Yuzhu Zhang, Yuchen Liu, Jing Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Yuzhu Zhang, Yuchen Liu, Jing Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature
Qinqin Liu, Xianhuan Yu, Qibin Tang, et al.
Anti-Cancer Drugs (2023)
Closed Access | Times Cited: 2
Qinqin Liu, Xianhuan Yu, Qibin Tang, et al.
Anti-Cancer Drugs (2023)
Closed Access | Times Cited: 2
Hepatic Arterial Infusion Chemotherapy with or without Lenvatinib for Unresectable Cholangiocarcinoma: A Single-Center Retrospective Study
Yajing Wang, Zhanqi Wei, Zheng Zhang, et al.
Hepatic Oncology (2023) Vol. 10, Iss. 2
Open Access | Times Cited: 2
Yajing Wang, Zhanqi Wei, Zheng Zhang, et al.
Hepatic Oncology (2023) Vol. 10, Iss. 2
Open Access | Times Cited: 2
Clinical outcomes of immune checkpoint inhibitor combined with other targeted or immunological therapy regimens for the treatment of advanced bile tract cancer: a systematic review and meta-analysis
Jianpeng Zhou, Jia Li, Zhongqi Fan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Jianpeng Zhou, Jia Li, Zhongqi Fan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Phase Ⅱ Study of Combined Sintilimab and Anlotinib with Gemcitabine plus Cisplatin in Advanced Biliary Tract Cancer: Efficacy, Safety and Optimize Dose
Jingjing Li, Shurui Zhou, Xiaoqing Xu, et al.
Research Square (Research Square) (2024)
Closed Access
Jingjing Li, Shurui Zhou, Xiaoqing Xu, et al.
Research Square (Research Square) (2024)
Closed Access
Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies
Yidan Lou, Yijing Chen, Kaibo Guo, et al.
Biomarkers in Medicine (2024) Vol. 18, Iss. 15-16, pp. 703-715
Closed Access
Yidan Lou, Yijing Chen, Kaibo Guo, et al.
Biomarkers in Medicine (2024) Vol. 18, Iss. 15-16, pp. 703-715
Closed Access
Camrelizumab combined with gemcitabine and apatinib in treating advanced PD ‐L1 ‐positive biliary tract cancers
Yitong Tian, Changxian Li, Ke Jin, et al.
Cancer Science (2024)
Open Access
Yitong Tian, Changxian Li, Ke Jin, et al.
Cancer Science (2024)
Open Access
